SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)

References

• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;2:77–82.
   Google Scholar
• Chaudhury A, Duvoor C, Dendi VSR, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Hallow KM, Greasley PJ, Helmlinger G, et al. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol. 2018;315(5):F1295–306.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531.
   PubMed Web of Science ®Google Scholar
• Asano T, Ogihara T, Katagiri H, et al. Glucose cotransporter and Na+/glucose cotransporter as molecular targets of antidiabetic drugs. Curr Med Chem. 2004;11:2717–2724.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–385.
   PubMed Web of Science ®Google Scholar
• Kuang H, Liao L, Chen H, et al. Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit. 2017;23:3737–3745.
   PubMed Web of Science ®Google Scholar
• Duann P, Lin PH. Mitochondria damage and kidney disease. Adv Exp Med Biol. 2017;982:529–551.
   PubMed Web of Science ®Google Scholar
• Andrianesis V, Glykofridi S, John D. The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab. 2016;7(5–6):212–228.
   PubMed Web of Science ®Google Scholar
• Roder PV, Geillinger KE, Zietek TS, et al. The Role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014;9(2):e89977.
   PubMed Web of Science ®Google Scholar
• Augustin R. The protein family of glucose transport facilitators: it’s not only about glucose after all: critical review. IUBMB Life. 2010;62:315–333.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Sharma K, et al. Renal sodium glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277.
   PubMed Web of Science ®Google Scholar
• Wright E, Turc E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447:510–518.
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt K, Gunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–112.
   PubMed Web of Science ®Google Scholar
• Wright E, Loo D, Hirayama B. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
   PubMed Web of Science ®Google Scholar
• Wright E, Hirayama B, Loo D. et al. Intestinal sugar transport. L. Johnson, editor. Physiology of Gastrointestinal Tract. 3rd ed. New York, NY:Raven Press; 1994. p.1751–1772.
   Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32–43.
   PubMed Web of Science ®Google Scholar
• Coady M, Wallendorff B, Gagnon D, et al. Indentification of a Novel Na+/myo-Inositol Cotransporter. J Biol Chem. 2002;277:35219–35224.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo R. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type2 diabetes mellitus. Endocr Pract. 2008;14:782–790.
   PubMedGoogle Scholar
• Vallon V, Richter K, Blantz R, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569–2576.
   PubMed Web of Science ®Google Scholar
• Guyton A, Hall J. Chapter 27: urine formation by the kidneys: II tubular processing of the glomerular filtrate. In: Guyton A, Hall J, editors. Textbook of Medical Physiology. 11th ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2006. p. 327–347.
   Google Scholar
• Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087–2097.
   PubMed Web of Science ®Google Scholar
• Hediger M, Rhoads D. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. 1994;74:993–1026.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson P, Ward J, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo R. Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport. J Intern Med. 2014;276:352–363.
   PubMed Web of Science ®Google Scholar
• Scholl-Burgi S, Santer R, Ehrich J. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004;19:2394–2396.
   PubMed Web of Science ®Google Scholar
• Mosley JF, Smith L, Everton E, et al. Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: A drug class overview. Pharm Ther. 2015;40(7):451–462.
   Google Scholar
• Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875–883.
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11(2):79–88.
   PubMed Web of Science ®Google Scholar
• Ehrenkranz J, Lewis N, Kahn C, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–38.
   PubMed Web of Science ®Google Scholar
• White J. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28:5–10.
   Google Scholar
• Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48:1794–1800.
   PubMed Web of Science ®Google Scholar
• Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type2 diabetes mellitus: review. J Pharm Pharmacol. 2013;65:317–327.
   PubMed Web of Science ®Google Scholar
• Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type2 diabetes mellitus. J Clin Pharmacol. 2010;50:623–635.
   PubMed Web of Science ®Google Scholar
• Nair S, Wilding JPH. Sodium Glucose Cotransporter. 2 Inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34–42.
   PubMed Web of Science ®Google Scholar
• Hummel CS, Lu C, Liu J, et al. Structural selectivity of human SGLT inhibitors. AJP: Cell Physiol. 2011;302(2):C373–C382.
   Google Scholar
• Ferrannini E, Ramos S, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double- blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217–2224.
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
   PubMed Web of Science ®Google Scholar
• Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:1–15.
   PubMed Web of Science ®Google Scholar
• Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7:e30555.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aggarwal N, Polidori D, et al. Dose ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
   PubMed Web of Science ®Google Scholar
• Wilding J, Norwood P, T’joen C, et al. A study of dapagliflozin in patients with type2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–1662.
   PubMed Web of Science ®Google Scholar
• Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213–219.
   PubMed Web of Science ®Google Scholar
• Scheen A. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213–225.
   PubMed Web of Science ®Google Scholar
• Wilding J, Ferrannini E, Fonseca V, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15:403–409.
   PubMed Web of Science ®Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613–621.
   PubMed Web of Science ®Google Scholar
• Veltkamp S, Kadokura T, Krauwinkel W, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839–851.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Ferrannini E, Wilding J, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268–277.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ö L, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
   PubMed Web of Science ®Google Scholar
• Bailey C, Gross J, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet. 2010;375:2223–2233.
   PubMed Web of Science ®Google Scholar
• Hansen HH, Jelsing J, Hansen CF, et al. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat. J Pharmacol Exp Ther. 2014;350:657–664.
   PubMed Web of Science ®Google Scholar
• Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2015;24:1–9.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Dandona P, Phillip M, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and −2. Diabetes Care. 2019;pii: dc181983.
   Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation. 2014;129:587–597.
   PubMed Web of Science ®Google Scholar
• Lamos E, Younk L, Davis S. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23:875–882.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019;365:l1328.
   PubMedGoogle Scholar
• Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the in tandem program. Diabetes Care.2019;42(5):919-930. .
   Google Scholar
• McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61(10):2126–2133.
   PubMed Web of Science ®Google Scholar
• Škrtić M, Yang G, Perkins B, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57:2599–2602.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Porrini E, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–2068.
   PubMed Web of Science ®Google Scholar
• Jerums G, Premaratne E, Panagiotopoulos S, et al. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093–2104.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol. 2014;306:F194–F204.
   PubMed Web of Science ®Google Scholar
• Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013;170:519–531.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi S, Lachin J, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215–222.
   PubMed Web of Science ®Google Scholar
• Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcomes trials. Lancet. 2019 Jan 5;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Oliva R, Bakris G. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330–339.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–428.
   PubMed Web of Science ®Google Scholar
• Majewski C, Bakris G. Blood pressure reduction: an added benefit of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429–430.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Wu J, Foote C, Blomster J, et al. Effects of sodium glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
   PubMed Web of Science ®Google Scholar
• Kaji K, Nishimura N, Seki K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2017;10:1002–1193.
   Google Scholar
• Linda AV, Brennan KS, Katarina M, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol metabolisms. 2016; 5(10):1048–1056.
   Google Scholar
• Tsugumichi S, Shuichi O, Eijiro Y, et al. Effect of dapagliflozin on colon cancer cell. Endocr J. 2015;62(12):1133–1137.
   PubMed Web of Science ®Google Scholar
• Scafoglioa C, Hirayamab BA, Kepea V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112:E4111–9.
   PubMed Web of Science ®Google Scholar
• Li H, Tong CW, Leung Y, et al. Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase inhibitor-resistant lung cancer. Front Oncol. 2017;7:288.
   PubMed Web of Science ®Google Scholar
• Ptaszynska A, Cohen S, Messing E, et al. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther. 2015;6:357–375.
   PubMed Web of Science ®Google Scholar
• Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type2 diabetes mellitus. Diabetes Ther. 2014;5:73–96.
   PubMed Web of Science ®Google Scholar
• Washburn WN. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opin Ther Pat. 2012;22(5):483–494.
   PubMed Web of Science ®Google Scholar
• Merck patent Gmbh, Tsaklakidid C, Beier N. Glucopyranoside derivatives. 2009. (WO2009124638).
   Google Scholar
• Sanofi SA, Frick W, Glombik H, et al. Novel aromatic glycoside derivatives, medicament containing said compounds, and the use thereof; 2011 . (WO2011107494(A1))
   Google Scholar
• TFChem, C-arylglycoside compounds for the treatment of diabetes and obesity; 2010. (WO2009121939).
   Google Scholar
• Pharmaceutical A, Gant TG, Shahbaz M thoxyphenylmethyl inhibitors of SGLT2. WO2010048358; 2010.
   Google Scholar
• Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824.
   PubMedGoogle Scholar
• Chen Y, Fu X, Li X, Shanghai Sun Sail Pharmaceutical Science & Technology Co. Ltd. C-aryl glucoside derivative, preparation method and applications thereof. CN104109154 (A). 2014.
   Google Scholar
• Zhao J, Hu W, Xu D, et al. Chia Tai Tianqing Pharmaceutical Group co ltd. C-triaryl glucoside SGLT-2 inhibitors. WO2014146606 (A1). 2014.
   Google Scholar
• Chen Y, He L, Zhu X Shanghai Sun Sail Pharmaceutical Science & Technology co ltd. C-benzo five-membered heteroaromatic aryl glucoside derivative as well as preparation method and application thereof. CN105294785 (A). 2016.
   Google Scholar
• Gao D, Yang H, Wang P, Shanghai Dinuo Pharmaceutical co ltd. C-aryl indican derivative, pharmaceutical composition thereof, preparation method thereof and uses thereof. JP2017511383 (A). 2017.
   Google Scholar
• Wang Y, He R, Jin Y, Zhejiang Yongtai Tech co ltd; Zhejiang Yongtai Pharmaceutical co ltd. Compound containing adamantane structure and serving as SGLT-2 inhibitor. CN107903231 (A). 2018.
   Google Scholar
• Lin J, Chen S, Li Y, Zhejiang Yongtai Tech Co. Ltd. Compound containing hydroxypiperidine structure and serving as SGLT-2 inhibitor. CN107903247 (A). 2018.
   Google Scholar
• He R, Wang Y, Jin Y Zhejiang Yongtai Tech co ltd; Yongtai Pharmaceutical ltd. Compound containing cyclohexane structure and severed as SGLT-2 inhibitor. CN107880006 (A); 2018.
   Google Scholar
• Jain R, Trehan S, Das J, et al. Panacea Biotech Limited. Novel SGLT inhibitors. US2014378540 (A1). 2014.
   Google Scholar
• Wells K, Li X, Branum S, et al. Janssen Pharmaceutica NV. Process for the preparation of compounds useful as inhibitors of SGLT-2. US2014206859 (A1). 2014.
   Google Scholar
• Li Y, Chen L, Xu B, et al. Sichuan Haisco Pharmaceutical co ltd. Oxa-thia-bicyclo [3.2.1] octane derivative, preparation method, and use of same. 2014. (WO2014206349 (A1)).
   Google Scholar
• Gu Z, Wen J, Wang H, et al. Guangdong Hec pharmaceutical Co. Ltd. Glucopyranose-based derivative and application of glucopyranose-based derivative in medicines. 2015. (CN104447893 (A)).
   Google Scholar
• Xu B, Lyu B, Xu G, et al. Theracos inc. Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors. 2015. (CN104334568 (A))
   Google Scholar
• Cai Z, Foshan Saiweisi Pharmaceutical Technology co ltd. Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application. CN104628672 (A). 2015.
   Google Scholar
• Cai Z, Foshan Saiweisi Pharmaceutical Technology co ltd. Alkoxy-substituted compounds containing methoxyphenyl thiophene amide structures and application. CN104725347 (A). 2015.
   Google Scholar
• Cai Z, Foshan Saiweisi Pharmaceutical Technology co ltd. Cyano-substituted double-target inhibitors containing methoxybenzene thiophene amide and application thereof. CN104725346 (A). 2015.
   Google Scholar
• Cai Z, Foshan Saiweisi Pharmaceutical Technology co ltd. Halogenophenylthiazole carboxylic acid amide compounds containing phenylamidine structures as well as preparation method and application thereof. CN104910097 (A). 2015.
   Google Scholar
• Cai Z, Foshan Saiweisi Pharmaceutical Technology co ltd. Nitrobenzothiazole carboxylic acid amide compounds containing phenylamidine structures and application. CN104628671 (A). 2015.
   Google Scholar
• Xu G, Binhua LV, Seed B, et al. Theracos Sub LLC. Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitors. NZ630408 (A). 2016.
   Google Scholar
• Kwee HS, Nam DK, Moon SL, et al. Hanmi Pharm Ind co ltd. 2,3-Dihydrobenzofuran derivatives as an sglt inhibitor and pharmaceutical composition comprising same. AR100420 (A1). 2016.
   Google Scholar
• Cho EH, Shin HJ, Kwon HS, et al. Samjin Pharm co ltd. Novel isoindolines derivatives, method of preparing thereof, and pharmaceutical composition including therof. KR20160097861 (A); 2016.
   Google Scholar
• Chen X, Omar P, Huang Q, et al. Zhenjiang San an Pharmaceutical co ltd. Isobenzofuran derivatives, pharmaceutical composition and preparation of derivatives, and application of derivatives. CN108640958 (A). 2018.
   Google Scholar
• Dong AN, Jia L. Allist Pharmaceuticals Inc. Spiroketal derivative and preparation method and application thereof. CN106892929 (A). 2017.
   Google Scholar
• Gaul M, Kuo GH, Xu G, et al. Janssen Pharmaceutica NV. Benzocyclobutane derivatives useful as dual sglt1/sglt2 modulators. WO2018089449 (A1). 2018.
   Google Scholar
• Kwak WY, Sung SY, Kim JH, et al. Dong A ST co ltd. SGLT-2 Novel Glucose derivatives of SGLT-2 inhibitor. KR20180098173 (A). 2018.
   Google Scholar
• Zhao G, Han S, Xie Y, et al. Tianjin Inst Pharm Research. Crystal form A of compound as well as preparation method and application thereof. CN104693192 (A). 2015.
   Google Scholar
• Zhao J, Pan B, Tian H Jiangsu hansoh Pharmaceutical; Univ Southeast. 1-(beta-D-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and L-phenylalanine eutectic compound and preparation method thereof. CN103965267 (A). 2014.
   Google Scholar
• Lin G, Li X, Liu Z, et al. Beijing Winsunny Pharmaceutical co ltd. Preparation method of SGLT-2 inhibitor compound. CN105481915 (A); 2016.
   Google Scholar
• Lin W, Zheng H, Lin C, et al. Porton Fine Chemicals ltd. SGLT-2 inhibitor intermediate synthesis method. CN106316803 (A). 2017.
   Google Scholar
• Kwak WY, Sung SY, Kim JH, et al. Dong-A ST co ltd. Novel solvate of dapagliflozin and preparation method thereof. WO2017099496. (A1). 2017
   Google Scholar
• Zhang L, Wang Y Youngene Therapeutics co ltd. Amine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof. CA3016273 (A1). 2017.
   Google Scholar
• Nair R, Pv R, Sk D, et al. Indoco Remedies ltd. Process for the preparation of SGLT inhibitor compounds. US2018016290 (A1). 2018.
   Google Scholar
• Zheng X, Zhang Y, Fu C, Hangzhou Cheminspire Tech co ltd. Preparation method of ertugliflozin and intermediate of ertugliflozin. CN107382952 (A). 2017.
   Google Scholar
• Zheng X, Zhang Y, Wu Y Hangzhou Cheminspire Tech co ltd. Preparation methods of SGLT-2 diabetes inhibitors and intermediates thereof. CN107163092 (A). 2017.
   Google Scholar
• Claudius W, Thomas Adam D, Marbod H, et al. Boehringer Ingelheim Vetmedica GMBH. Liquid pharmaceutical compositions comprising SGLT-2 inhibitors. MX2018002383 (A). 2018.
   Google Scholar
• Mundla MV, Malyala S, Narani CP, et al. Emmennar Pharma Private ltd. Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof. US2018346502 (A1). 2018.
   Google Scholar
• Wienrich M, Mayoux E Boehringer Ingelheim International Gmbh. SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents. AU2012264736 (A1). 2013.
   Google Scholar
• Eickelmann P, Mark M, Leo JS, et al. Boehringer Ingelheim int. SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia. JP2015042691 (A). 2015
   Google Scholar
• Liu K, Lang Y Shandong Target Drug Research Co. Ltd. Medical application of diacerein in treating diabetes and diabetic nephropathy. CN103655535 (A). 2014.
   Google Scholar
• Naoki K Taisho Pharma co ltd. Combinations of SGLT-2 inhibitors and antihypertensive drugs. EP2891499 (A1). 2015.
   Google Scholar
• Broedl CU, Cherney D, Daiber A, et al. Therapeutic uses of empagliflozin. Boehringer Ingelheim int. AU2014247091(A1). 2015.
   Google Scholar
• Broedl U, Von EM, Macha S, et al. Boehringer Ingelheim int. Pharmaceutical composition, methods for treating and uses thereof. US9949998(B2). 2018.
   Google Scholar
• Naik R, Ommen E, Rusnak JM, et al. Merck sharp & Dohme, Pfizer. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease.US2017304262 (A1). 2017.
   Google Scholar
• Albrecht- Kupper B, Bayer VS. Selective partial adenosine a1 receptor agonists in combination with SGLT-2 inhibitors. WO2018153900 (A1). 2018
   Google Scholar
• Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173–1178.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–2022.
   PubMed Web of Science ®Google Scholar
• Taylor S, Blau J, Rother K. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
   PubMed Web of Science ®Google Scholar